CHARLOTTESVILLE, Virginia, September 9 /PRNewswire/ -- Biovista Inc. today announced that BVA-201, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-201 is an existing drug that Biovista repositioned in MS and is aimed at neuroprotection. It was shown to have both efficacy in reducing symptoms and no toxic effects in this well established model of MS.
"This is our second success in MS in a period of 6 months, with BVA-201 showing efficacy levels closely comparable to those of dexamethasone," said Aris Persidis, Ph.D., President of Biovista. "Histology results are also encouraging, since they seem to confirm our expectations regarding the compound's mechanism of action. What is even more important is that BVA-201 has a known and very favorable safety profile and is already approved for chronic use," Dr. Persidis added.
For a non-confidential information pack on BVA-201 contact Biovista at firstname.lastname@example.org.
About Biovista's BVA-201 trial in the MS EAE-MOG model
MS is a chronic inflammatory neurological disease. It is the most
frequent non-traumatic disabling neurologic disease among young adults, with
over 2.5 million patients worldwide. In the animal proof-of-concept trial,
BVA-201 was compared to dexamethasone, a potent anti-inflammatory and
immunosuppressive drug that is efficient in accelerating the recovery from MS
relapses but too toxic for chronic use. BVA-201 induced a statistically
significant reduction of EAE severity, the magnitude of which was directly
comparable to that caused by dexamethasone. Furthermore, BVA-201 protected
neural axons and
|SOURCE Biovista Inc.|
Copyright©2009 PR Newswire.
All rights reserved